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CUEDC2, a CUE-domain-containing protein, modu-
lates inflammation, but its involvement in tumorigen-
esis is still poorly understood. Here, we report that
CUEDC2 is a key regulator of macrophage function
and critical for protection against colitis-associated
tumorigenesis. CUEDC2 expression is dramatically
upregulated during macrophage differentiation, and
CUEDC2 deficiency results in excessive production
of proinflammatory cytokines. The level of CUEDC2
in macrophages is modulated by miR- 324-5p. We
find that Cuedc2 KO mice are more susceptible to
dextran-sodium-sulfate-induced colitis, and macro-
phage transplantation results suggest that the
increased susceptibility results from the dysfunction
of macrophages lacking CUEDC2. Furthermore, we
find that Cuedc2 KO mice are more prone to colitis-
associated cancer. Importantly, CUEDC2 expression
is almost undetectable in macrophages in human
colon cancer, and this decreased CUEDC2 expres-
sion is associated with high levels of interleukin-4
and miR-324-5p. Thus, CUEDC2 plays a crucial role
in modulating macrophage function and is associ-
ated with both colitis and colon tumorigenesis.INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy
(Saleh and Trinchieri, 2011; Terzic et al., 2010). It is known that
intestinal inflammation is one of the major causes leading to
CRC (Bouma and Strober, 2003). Inflammatory bowel diseases
(IBDs) are inflammatory disorders of the intestinal tract, which1982 Cell Reports 7, 1982–1993, June 26, 2014 ª2014 The Authorsoften result in the development of colitis-associated cancer
(CAC) (Fiocchi, 1998). Like many solid tumors, colon cancers
are infiltrated by a variety of immune cells, including macro-
phages (Qian and Pollard, 2010). Macrophages are the most
prominent innate immune cells that play a central role in host de-
fense and inflammation. Derived from monocytes, the precursor
cells, macrophages can be found in many tissues throughout the
body (Gordon, 2003; Gordon and Taylor, 2005). With a high level
of plasticity, macrophages can be polarized into distinct sub-
types with diverse functions in different physiological or patho-
logical context (Gordon, 2003; Lawrence and Natoli, 2011;
Murray and Wynn, 2011). Macrophages found in tumors are
commonly termed as tumor-associated macrophages (TAMs).
Animal model and clinical studies suggest that TAMs facilitate
tumor progression and metastasis in various ways, e.g., produc-
ing proangiogenic factors, immune regulation, and tissue
remodeling (Murdoch et al., 2008; Qian and Pollard, 2010).
Tumor-derived molecules, such as interleukin (IL)-4, can render
macrophage characteristic state to promote tumor growth (Go-
cheva et al., 2010; Li et al., 2008b; Todaro et al., 2007). However,
the underlying mechanisms of TAM function remain obscure.
Recent studies revealed that macrophages promote tumori-
genesis by producing tumor-promoting cytokines (Grivennikov
et al., 2009; Terzic et al., 2010). Normally, the production of
proinflammatory cytokines is under the tight control of several
signaling pathways, amongwhich NF-kB functions as the central
mediator (Baltimore, 2011; Lawrence, 2009; Vallabhapurapu and
Karin, 2009). Deficiency of negative regulators of NF-kB
signaling, e.g., NLRP12 and Cylindromatosis (CYLD), result in
hypersusceptibility to colon inflammation and tumorigenesis
(Allen et al., 2012; Zaki et al., 2011; Zhang et al., 2006).
MicroRNAs are evolutionarily conserved, noncoding RNAs.
MicroRNA recognizes the targeted mRNA via base-pairing bind-
ing of its 50 ‘‘seed’’’ region to the targeting site, which locates
mainly in the 30 UTR of mRNA (Fabian et al., 2010; Valencia-San-
chez et al., 2006). Along with core argonaute proteins, microRNA
forms the RNA-induced silencing complex (RISC), leading to
mRNA decay and inhibition of protein synthesis (Gibbings
et al., 2009; Rehwinkel et al., 2005). Accumulating data have
established a pivotal role of microRNAs in cancer development
(Di Leva et al., 2014; Lee and Dutta, 2009). Although previous
studies identified alteredmicroRNA expression in CRC (Garofalo
and Croce, 2011; Schetter et al., 2012), the detailed mechanism
of microRNAs in the development of CRC is still unclear.
We have previously reported that CUEDC2 regulates NF-kB
signaling (Li et al., 2008a), suggesting that it is potentially an
important regulator of inflammation. In current study, we found
that miR-324-5p modulated CUEDC2 upregulation during
monocyte to macrophage differentiation, and the high level of
CUEDC2 expression in macrophages prevented inappropriate
inflammatory responses. We further showed that, in the tumor
microenvironment, elevated IL-4 was associated with the upre-
gulation of miR-324-5p and the decrease of CUEDC2 in TAMs.
Thus, the miR-324-5p-regulated CUEDC2 expression is critical
for maintaining the appropriate function of macrophages, and
their dysregulation is associated with colon inflammation and
tumorigenesis.
RESULTS
CUEDC2 Is Upregulated during Monocyte to
Macrophage Differentiation
To investigate the physiological role of CUEDC2 in inflammation,
we examined whether CUEDC2 was involved in regulation of
macrophage function using the Cuedc2/ mice we generated
(Figures S1A and S1B). We first checked the expression of
CUEDC2 in mouse monocytes and macrophages. Primary
monocytes were isolated from bone marrow cells of wild-type
(WT) and the Cuedc2/ mice. The bone-marrow-derived mac-
rophages (BMDMs) were generated by treating bone marrow
cells with recombinant mouse macrophage colony-stimulating
factor (rmM-CSF) (Krausgruber et al., 2011; Satoh et al., 2010).
The purity of monocytes and macrophages was determined by
staining with the specific surface markers (Figure S1C, upper
panels). Interestingly, in WT mice, whereas CUEDC2 was
marginally expressed in monocytes, the expression levels of
CUEDC2 in macrophages were dramatically increased (Fig-
ure 1A). This result suggested that CUEDC2 was upregulated
when monocytes differentiate to macrophages. This finding
was confirmed in monocytes and BMDMs from more than 20
WTmice. There was noCUEDC2 expression in either monocytes
and macrophages in Cuedc2/ mice (Figure 1B). The high
expression of CUEDC2 was also detected in peritoneal macro-
phages of WT mice, which were differentiated in vivo (Fig-
ure S1D). Notably, the upregulation of CUEDC2 was not
essential for monocyte-macrophage differentiation, because
Cuedc2/ macrophages were differentiated normally, as veri-
fied by flow cytometry analysis of the monocyte marker Ly6C
and macrophage marker F4/80 (Zhang et al., 2012) (Figure S1C).
We next investigated whether CUEDC2 was involved in the
polarization ofM1 andM2macrophages.When treatedwith lipo-
polysaccharide (LPS) and interferon-g (IFN-g), compared to WT
BMDMs, Cuedc2/ BMDMs produced much larger amounts of
inducible nitric oxide synthase (iNOS), a M1 marker. In contrast,Cwhen treated with interleukin (IL)-4, BMDMs from WT, and
Cuedc2/ mice produced the similar amount of arginase 1, a
M2marker (Figure S1E). We also detected themRNA expression
of M1-associated genes, IL-6, IL-1b, and IL-12p40, as well as
M2-associated genes, chemokine (C-C motif) ligand (CCL)-17,
FIZZ1, and YM-1 with quantitative PCR (qPCR) analysis (Fig-
ure S1F). Collectively, these data indicated that CUEDC2
inhibits M1 macrophage polarization but is dispensable for M2
polarization.
We then evaluated the role of CUEDC2 in proinflammatory
cytokine production in response to LPS. BMDMs from WT and
Cuedc2/ mice were treated with LPS for 4 hr and then
collected for total RNA extraction. Transcription of four proin-
flammatory factors, IL-6, tumor necrosis factor (TNF)-a, IL-12,
and IL-1b, were measured by qPCR analysis. Significantly
greater inductions of these genes in Cuedc2/ macrophages
were observed than those in WT macrophages (Figure 1C).
Consistent with these results, ELISA analysis showed higher
secretion of IL-6, TNF-a, and IL-12 in LPS-treated Cuedc2/
BMDMs (Figure 1D). These results were further confirmed in
peritoneal macrophages isolated from WT and Cuedc2/
mice, which were injected with LPS intraperitoneally (Figure 1E).
The increased expression levels of these proinflammatory fac-
tors in Cuedc2/ macrophages are most likely due to the
increased NF-kB signaling in the cells (Figure S1G).
Taken together, these data demonstrated that CUEDC2
serves an important function in macrophages to control the pro-
duction of proinflammatory cytokines through regulating NF-kB
signaling.
CUEDC2 Plays a Similar Role in Regulating Cytokine
Production in Human Macrophages
To be sure that the above observations in murine cells also
applied to human cells, we next tested the involvement of
CUEDC2 in human macrophage function. Primary monocytes
were purified from peripheral blood and differentiated to
macrophages using treatment of recombinant human granulo-
cyte-macrophage colony-stimulating factor (rhGM-CSF) or
rhM-CSF (Lawrence et al., 2005; Satoh et al., 2010). Consistent
with the results in murine cells, a drastic increase of CUEDC2
expression was seen during the human macrophage differenti-
ation (Figure 2A). This result was confirmed in monocytes and
macrophages from more than 30 donors. When CUEDC2
expression was knocked down using specific CUEDC2 small
interfering RNA (siRNAs), the production of proinflammatory
cytokines, IL-6, TNF-a, IL-12, and IL-1b, was significantly
elevated in response to LPS treatment (Figures 2B and 2C).
Thus, the results from human macrophages confirmed that
CUEDC2 is critical for regulating macrophage function in both
human and mouse.
MiR-324-5p Regulates the Differential Expression of
CUEDC2 in Monocytes and Macrophages
The finding that CUEDC2 was only highly expressed in macro-
phages but not in monocytes indicated that CUEDC2 expression
was tightly regulated during monocyte-macrophage differentia-
tion. To understand how the differential expression of CUEDC2
in monocytes and macrophages is regulated, we first examinedell Reports 7, 1982–1993, June 26, 2014 ª2014 The Authors 1983
Figure 1. Upregulated CUEDC2 Expression during Macrophage Differentiation Regulates Cytokine Production
(A and B) Immunoblot analysis of CUEDC2 in monocytes and BMDMs from WT mice (A) or both WT and Cuedc2/ mice (B).
(C) BMDMs from WT and Cuedc2/ mice were treated with LPS for 4 hr, and mRNA levels of IL-6, TNF-a, IL-12, and IL-1b were analyzed by qPCR. Data were
normalized to GAPDH mRNA.
(D) BMDMs fromWT and Cuedc2/mice were challenged with LPS for 12 hr. The culture supernatant was harvested and analyzed for IL-6, TNF-a, and IL-12 by
ELISA. Values were normalized to cell numbers.
(E) WT and Cuedc2/ mice were injected with LPS intraperitoneally, and 3 hr later peritoneal macrophages (Mf) were isolated and analyzed for indicated
cytokines and chemokines with qPCR.
Data represent at least three independent experiments, error bars represent SEM. *p < 0.05, **p < 0.01 (C–E). See also Figure S1.
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Figure 2. CUEDC2 Plays a Similar Role in
Regulating Cytokine Production in Human
Macrophages
(A) Immunoblot analysis of CUEDC2 in human
monocytes (Mo) and macrophages (Mf) differen-
tiated with rhGM-CSF or rhM-CSF.
(B) CUEDC2 (CUE) or nontargeting (NT) siRNA-
transfected macrophages were treated with LPS,
followed by qPCR analysis of indicated mRNAs.
Data represent at least three independent ex-
periments; error bars represent SEM. *p < 0.05,
**p < 0.01.
(C) Immunoblot analysis of CUEDC2 in siRNA-
transfected macrophages in (B).
a-tubulin blots indicate loading of lanes (A and C).the expression levels of CUEDC2mRNA in monocytes andmac-
rophages by qPCR. Surprisingly, despite the great difference of
CUEDC2 protein levels in monocytes and macrophages, there
was no detectable change in CUEDC2 mRNA levels between
these two types of cells (Figure 3A), indicating that the elevation
of CUEDC2 expression is unlikely to be regulated at transcrip-
tional level. Our previous study showed that microRNAs
play an important role in regulating gene expression during
monocyte-macrophage differentiation (Li et al., 2010), we there-
fore tested whether the differential expression of CUEDC2
in these cells was modulated by microRNAs. Using the data-
bases Memorial Sloan-Kettering Cancer Center microRNA and
Targetscan, we identified putative targeting sites of three
microRNAs, miR-324-5p, miR-326, miR-330-5p, in the 30 UTR
of CUEDC2 mRNA (Figure S2A). Although all these three
microRNAs have higher expression levels in monocytes than
macrophages (Figure 3B), only miR-324-5p mimic showed
distinct inhibitory effect on CUEDC2 expression (Figure 3C).
Therefore, we mainly focused on miR-324-5p in the following
studies. As expected, the inhibitor of miR-324-5p elevated
CUEDC2 expression in monocytes (Figures 3D, S2B, and
S2C). In accordance with sequence alignment analysis, which
showed that the targeting sites of miR-324-5p in the 30 UTR of
CUEDC2 mRNA are conserved in mammals (Figure S2D), miR-
324-5p mimic also inhibited CUEDC2 expression in murine
BMDMs (Figure S2E). Therefore, miR-324-5p is likely to be
responsible for the differential expression of CUEDC2 in mono-
cytes and macrophages. In addition, because miR-324-5p
mimic affected the expression of CUEDC2 protein withoutCell Reports 7, 1982–199changing the CUEDC2 mRNA level (Fig-
ures 3C and S2F), it is possible that
miR-324-5p regulates the CUEDC2
expression at translational level.
To further confirm the regulation of
miR-324-5p on CUEDC2 expression is
through the predicted targeting site in
CUEDC2 30 UTR, we generated luciferase
fusion constructs with WT and mutant
30 UTRs of CUEDC2 (Figure 3E). Together
with a herpes simplex virus thymidine
kinase (HSV-TK) promoter-driven Renilla
luciferase plasmid, the luciferase fusionconstructs with WT 30 UTR and the mutant were, respectively,
transfected into HeLa human cervical cancer cells. The Firefly
luciferase activity was normalized to Renilla luciferase activity
for transfection efficiency. In the presence of miR-324-5p, the
luciferase activity was markedly inhibited, whereas the mutation
of the targeting site fully abolished the inhibitory effect of miR-
324-5p (Figure 3F). These data demonstrated that miR-324-5p
directly targeted mRNA of CUEDC2. In line with the role of
CUEDC2 in the macrophage function, the presence of miR-
324-5p mimic in macrophages led to the increased production
of proinflammatory cytokines. The expression level of CUEDC2
in macrophages was crucial for controlling cytokine production
because ectopic expression of CUEDC2 markedly inhibited the
effect of miR-324-5p on the cytokine expression (Figures 3G
and S2G).
CUEDC2 Expression in Macrophage is Critical for
Protection against Colitis
Dysregulation of macrophage function is often associated
with many inflammatory diseases, including IBD (Bouma and
Strober, 2003; Fiocchi, 1998; Kaser et al., 2010). To investigate
whether CUEDC2 is involved in colitis development, we adop-
ted the dextran sodium sulfate (DSS)-induced colitis mouse
model, a widely used experimental model for studying the
human IBD (Wirtz et al., 2007). In this model, mice were
subjected to oral administration of 2.5% DSS in drinking
water for 6 days, followed by regular drinking water for
3 days. Cuedc2/ mice suffered from significantly increased
body weight loss (Figure 4A), rectal bleeding, and diarrhea3, June 26, 2014 ª2014 The Authors 1985
Figure 3. MiR-324-5p Regulates the Differential Expression of CUEDC2 between Monocytes and Macrophages
(A) qPCR analysis of CUEDC2 mRNA in monocytes (Mo) and macrophages (Mf) presented relative to GAPDH mRNA.
(B) qPCR analysis of the expression of indicated microRNAs in human monocytes (Mo) and macrophages (Mf). Data presented as relative quantification
compared with the expression of small RNA U6.
(C) Immunoblot analysis of lysates of macrophages 48 hr after transfection of microRNA mimics or control mimics (Ctrl). Numbers below lanes are densitometry
(hCUEDC2 relative to a-tubulin).
(D) Immunoblot analysis of lysates of monocytes 24 hr after transfection of miR-324-5p inhibitor or control inhibitor (Ctrl). Numbers below lanes are densitometry
(hCUEDC2 relative to a-tubulin).
(E) CUEDC2 mRNA 30 UTR sequence of CMV luciferase constructs used for microRNA reporter assays, showing predicted pairing with the target site and the
mutant (MUT) sequences.
(F) HeLa cells cotransfectedwithWT ormutated 30 UTRof CUEDC2 reporter (Firefly Luciferase) constructs andmiR-324-5pmimics or control mimics, plus Renilla
luciferase plasmid. Luciferase activity was measured 48 hr after transfection, and the Firefly Luciferase activity was normalized for transfection efficiency to
Renilla luciferase activity.
(G) Human macrophages were transfected with control or miR-324-5p mimics for 24 hr, and then the cells were infected with lenti-virus-expressing Flag-tagged
CUEDC2 or Flag vector. The cells were treated with LPS for 4 hr, and total RNAs were extracted for qPCR analysis for indicated mRNAs.
Data represent means ± SEM (A, B, F, and G). See also Figure S2.
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Figure 4. CUEDC2 Expression in Macro-
phages is Critical for Protection against
Colitis
(A) WT and Cuedc2/ mice were subjected to
oral administration of 2.5% DSS for 6 days, fol-
lowed by regular drinking water for 3 days.
Body weight changes were monitored throughout
the study. Cuedc2/ mice (n = 11), WT mice
(n = 12).
(B) Mice were sacrificed 9 days after starting DSS
administration, and colon lengths from WT mice
(n = 9) and Cuedc2/ mice (n = 8) were
measured. Data represent means ± SEM.
(C) Typical colon appearance (left panels, arrow-
heads indicate borders of ulcers; scale bar
represents 500 mm; right panels, enlarged red
rectangle area from left panels accordingly; scale
bar represents 125 mm).
(D) Semiquantitative histological scores of colonic
sections from WT mice (n = 9) and Cuedc2/
mice (n = 8); data represent means ± SEM.
(E) WT and Cuedc2/ mice (n = 5, each group)
were injected intravenously with peritoneal mac-
rophages (3 3 106 cells/mouse) from WT mice or
Cuedc2/ mice twice. Body weight changes
were monitored throughout the study.
(F) Disease activity index of the macrophage
transplanted mice were measured daily.
Data represent means ± SEM. *p < 0.05, **p <
0.01 (A, E, and F). See also Figure S3.(Figures S3A and S3B), whereas WT mice started to recover
from day 8 after the initiation of the DSS treatment. Colons of
Cuedc2/ mice were significantly shorter than those of WT
mice (Figures 4B and S3C). The severity of DSS-induced colitis
in Cuedc2/ mice was further investigated by histological
examination of colon tissue sections. Massive disruption of
mucosal structures and thickened walls were observed in
Cuedc2/ mice, whereas only minor signs of ulceration were
found in colons of WT mice (Figure 4C). Semiquantitative
scoring of these histological parameters indicated that
Cuedc2/ mice suffered more severe colon inflammation (Fig-
ure 4D). Proinflammatory cytokines, IL-6, TNF-a, and IL-1b
were induced markedly more in colons from Cuedc2/ mice
(Figure S3D).
To further define the role of macrophage CUEDC2 in protect-
ing against colon inflammation, we transplanted macrophages
isolated from WT and Cuedc2/ mice into WT or Cuedc2/
mice. The experimental mice groups were WT mice with WT or
Cuedc2/ macrophages, and Cuedc2/ mice with WT or
Cuedc2/ macrophages. These animals were subjected toCell Reports 7, 1982–199DSS administration (Figure S3E). As ex-
pected, the WT and Cuedc2/ mice
that received Cuedc2/ macrophages
showed greater increases in weight loss
(Figure 4E) and increased overall disease
index (Figure 4F) compared with the WT
and Cuedc2/ mice that received WT
macrophages. Collectively, these data
suggested that CUEDC2 expression inmacrophages is critical for the protection against DSS-induced
colitis.
CUEDC2 Expression is Remarkably Reduced in
Macrophages Infiltrated in Human CRC
The observation that the deficiency of CUEDC2 in macrophages
led to the increased susceptibility of mice to DSS-induced colitis
prompted us to investigate whether CUEDC2 was involved in
colon tumorigenesis. We first performed immunohistology
analysis with specific antibodies against CUEDC2 and the
macrophage marker, CD68, in 36 human colon cancer samples
in order to examine the CUEDC2 expression in macrophages
infiltrated in the tumors. The expression of CUEDC2 in macro-
phages infiltrated in tumors was significantly lower than macro-
phages in normal adjacent tissues (Figures 5A and 5B). In
contrast, the expression level of CUEDC2 in colon cancer cells
showed no difference compared to adjacent normal epithelial
cells (Figures S4A and S4B). These data suggested that the
downregulation of macrophage CUEDC2 expression is associ-
ated with CRC.3, June 26, 2014 ª2014 The Authors 1987
Figure 5. CUEDC2 Expression Is Remarkably Reduced in Macro-
phages Infiltrated in Human CRC
(A) Representative images from immunohistochemical staining of CUEDC2 in
adjacent normal tissue and tumor tissue of CRC (upper panel). The corre-
sponding area of infiltrated macrophages was visualized by staining of the
CD68+ cells (macrophages) on the consecutive slides (bottom panel). On
upper panel, CUEDC2 expression in macrophages infiltrated in tumors was
significantly lower than that in normal adjacent tissues. Representative areas
of macrophages at higher magnification are displayed in the red square areas.
Scale bar represents 50 mm.
(B) Box plots for CUEDC2 expression scores. The horizontal lines in the box
represent the median, the boxes represent the first and third quartile,
respectively, and the vertical bars represent the range of data. CUEDC2
expression in macrophages infiltrated in tumor was compared to that in
adjacent normal tissues with Mann-Whitney U test, n = 36.
See also Figure S4.IL-4 Upregulates MiR-324-5p and Downregulates
CUEDC2 Expression in Macrophages
Because we found that miR-324-5p regulated CUEDC2 expres-
sion during macrophage differentiation, miR-324-5p is likely
responsible for the reduction of CUEDC2 expression in the mac-1988 Cell Reports 7, 1982–1993, June 26, 2014 ª2014 The Authorsrophages infiltrated in colon cancer tissues. To test this possibil-
ity, we isolated macrophages from fresh colon cancer tissues
immediately following surgical removal and analyzed the
abundance of miR-324-5p. As anticipated, comparing to macro-
phages isolated from adjacent normal tissues, the level of miR-
324-5p in macrophages from the tumor tissues was increased
(Figure 6A). However, the levels of CUEDC2 mRNA in macro-
phages from tumor tissues and adjacent normal tissues were
similar (Figure 6B).
We next investigated the possible mechanism responsible for
the miR-324-5p elevation in macrophages infiltrated in the tu-
mors. Due to the similarity of M2 macrophages to TAMs (Qian
and Pollard, 2010), we used IL-4-polarized M2 macrophages
to investigate how miR-324-5p was regulated in TAMs (Gordon
and Taylor, 2005). IL-4 treatment markedly induced the expres-
sion of miR-324-5p, whereas TNF-a and IL-1b had no effect (Fig-
ure 6C). Consistently, IL-4 treatment led to dramatic decrease of
CUEDC2 protein level without affecting CUEDC2 mRNA level
(Figures 6D and 6E). To investigate how IL-4 induced miR-324-
5p expression, we tried to identify transcription factors that
have putative binding sites in the promoter region of miR-324-
5p. By searching the databases TRANSFAC and JASPAR, we
found c-MYC as the candidate transcription factor of miR-324-
5p. In addition, a previous report showed that IL-4 regulates
c-MYC expression in macrophages (Pello et al., 2012); we
therefore tested the possible role of c-MYC in IL-4-induced
miR-324-5p expression. As shown in Figures S5A–S5C, IL-4
induced c-MYC expression, and knockdown of c-MYC inhibited
IL-4-induced miR-324-5p expression. Therefore, it is likely that
IL-4 regulates miR-324-5p expression through c-MYC.
Consistent with previous report (Todaro et al., 2008), a signif-
icant increase of IL-4 level in colon cancer tissues than adjacent
normal tissues was observed (Figures 6F and 6G). Collectively,
these data suggested that the elevated IL-4 in tumor microenvi-
ronmentmay be responsible for the decreased CUEDC2 expres-
sion in macrophages through inducing miR-324-5p.
CUEDC2 Deficiency Promotes the Development of CAC
To examine whether CUEDC2 deficiency promoted colon can-
cer development, WT and Cuedc2/ mice were injected with
the procarcinogen azoxymethane (AOM) and followed by three
cycles of oral DSS administration to trigger colon tumorigenesis
(Neufert et al., 2007) (Figure 7A). Body weight of those mice was
monitored daily following AOM treatment up to 12 weeks. Signif-
icantly more body weight loss was observed in Cuedc2/ mice
upon each DSS administration (Figure 7B). Compared with WT
mice, increased tumor number and size were observed in
Cuedc2/ mice colon (Figure 7C), and Cuedc2/ mice also
had remarkably higher tumor loads in the colon (Figure 7D).
Tumor numbers in Cuedc2/ mice were significantly larger
than those in WT mice (Figure S6A), and, in particular, many
more tumors bigger than 2 mm in diameter were observed in
Cuedc2/ mice (Figure 7E). Histological examination showed
that there was a large increase in adenomas with a higher degree
of dysplasia in Cuedc2/ mice, of which 50% were classified
as severe-grade dysplasia. In contrast, only 20% of the WT
mice displayed severe-grade dysplasia (Figure S6B and 7F).
Thus, CUEDC2 deficiency enhanced colon tumor progression.
Figure 6. IL-4 Induces the Elevation of MiR-
324-5p and Downregulation of CUEDC2
Expression in Macrophages
(A and B) QPCR analysis of miR-324-5p expres-
sion (A) and CUEDC2 mRNA (B) in macrophages
isolated from tumor or adjacent normal tissues
of CRC.
(C) Human macrophages were treated with IL-4
(20 ng/ml), TNF-a (20 ng/ml), and IL-1b (20 ng/ml)
for 24 hr and then analyzed with qPCR for miR-
324-5p.
(D and E) Immunoblot analysis for CUEDC2 pro-
tein level (D) and qPCR analysis for mRNA level of
CUEDC2 (E) in untreated and IL-4-treated human
macrophages.
(F) Representative images from immunohisto-
chemical staining of IL-4 in tumor and adjacent
normal tissues of CRC. Scale bar represents
100 mm.
(G) IL-4 expression scores are shown as box plots.
The horizontal lines in the box represent the
median, the boxes represent the first and third
quartile, respectively, and the vertical bars repre-
sent the range of data. We compared tumors with
matched adjacent normal tissues with Mann-
Whitney U test, n = 26.
Data represent means ± SEM (A–C and E). See
also Figure S5.DISCUSSION
CRC is a major cause of cancer-related death worldwide. It is
known that colon inflammation is an important risk factor of
CRC (Saleh and Trinchieri, 2011; Terzic et al., 2010). Our study
demonstrated that CUEDC2 is a key regulator of macrophage
function and is critical in protection against colon inflammation
and tumorigenesis. Although normally macrophages are thought
to be involved in antitumor immunity, the TAMs actually play an
important role in promoting cancer development. These TAMs
are capable to enhance angiogenesis, promote tissue remodel-
ing, and suppress antitumor immunity (Murdoch et al., 2008;
Qian and Pollard, 2010). Recent studies also suggest that
TAMs promote tumor growth through producing proinflamma-
tory cytokines, such as IL-6 and TNF-a (Deng et al., 2010; Gri-
vennikov et al., 2009). However, the molecular mechanisms of
the regulation of macrophage function remain obscure (Biswas
and Mantovani, 2010; Qian and Pollard, 2010). In this study,
we show that miR-324-5p regulates CUEDC2 expression during
macrophage differentiation, and deficiency of CUEDC2 in mac-
rophages results in excessive production of proinflammatory
cytokines, indicating that CUEDC2 is an important regulator of
macrophage function.Cell Reports 7, 1982–199CUEDC2 is thought to be ubiquitously
expressed in most tissues. However,
through analyzing the expression of
CUEDC2 during monocyte to macro-
phage differentiation, we found that
CUEDC2 was only highly expressed in
macrophages, but not in monocytes.
This surprising finding seems to be ageneral phenomenon because it is observed in both human
and mouse systems. Although the high expression of CUEDC2
in macrophages is not essential for the differentiation of these
cells, it is crucial for the function of macrophages as demon-
strated by the dramatically increased production of proinflam-
matory cytokines in Cuedc2/ macrophages in response to
inflammatory stimuli. Studies with experimental colitis have
suggested that abnormal activation of macrophages is the pri-
mary cause for development of colitis (Liu et al., 2011; Zaki
et al., 2011). Our in vivo experiments with macrophage trans-
plantation further support the important role of CUEDC2 ex-
pression in macrophages in protecting against excessive
inflammation. Therefore, the specific high level of CUEDC2
expression in macrophages may allow CUEDC2 to act as a
‘‘brake’’ for macrophage activation and maintains the appro-
priate function of macrophages.
NF-kB signaling pathway is a central player in the production
of tumorigenic factors, and its precise regulation in macro-
phages is essential for the proper functional maintenance of
these cells. It is known that the persistent activation of NF-kB
causes uncontrolled inflammation and leads to many inflamma-
tory diseases, as well as cancers (Qian and Pollard, 2010; Vallab-
hapurapu and Karin, 2009). We previously reported that3, June 26, 2014 ª2014 The Authors 1989
Figure 7. CUEDC2 Deficiency Promotes the
Development of Colitis-Associated Tumori-
genesis
(A) Scheme for CAC regimen. Cuedc2/ mice
(n = 22) and WT littermates (n = 22) received a
single injection of AOM (8.5 mg/kg) at day 0. Ten
days later, the mice were treated with three
rounds of 6 day DSS administration. Each round of
DSS treatment was followed by 2 weeks of re-
covery, and an additional 2 weeks were given after
the last treatment before the mice were sacrificed
at day 84.
(B) Body weight was monitored throughout the
whole procedure. Data are means ± SEM. *p <
0.05, **p < 0.01.
(C) Representative pictures of the AOM+DSS-
derived tumors in WT and Cuedc2/ mice. Scale
bar represents 0.5 cm.
(D and E) Tumor load (D), the sum of the diameters
of all tumors in each mouse, and the number of
tumor bigger than 2 mm in diameter (E) were
determined after mice were sacrificed. Data
represent means ± SEM.
(F) The representative images of hematoxylin-and-
eosin-stained sections of colons. Dashed lines
mark the borders between adenomas and normal
epithelium. Scale bar represents 125 mm.
See also Figure S6.CUEDC2 negatively regulates NF-kB signaling, suggesting that it
is a potentially important regulator responsible for preventing in-
flammatory damage to host tissues (Li et al., 2008a). In the cur-
rent study with Cuedc2/ mice, we provided in vivo evidence
that CUEDC2 is an important regulator of NF-kB pathway,
because NF-kB signaling is hyperactivated in response to in-
flammatory stimuli in Cuedc2 KO mice. Because early studies
have suggested that the loss of negative regulator of NF-kB
signaling (Allen et al., 2012; Anand et al., 2012; Zaki et al.,
2011; Zhang et al., 2006) leads to the increased colitis and colon
cancer, our finding that Cuedc2/ mice are significantly more
susceptible to experimental colitis, and CAC is most likely due
to the hyperactivation of NF-kB signaling as well.
Increasing numbers of microRNAs have been identified to
regulate both the initiation and the progression of many types
of cancers, including CRC (Garofalo and Croce, 2011). However,
the exact mechanism ofmicroRNAs function in colon tumorigen-
esis remains largely unknown. In this study, we identified a CRC-
associated microRNA, miR-324-5p, which has few functional
annotation to date. We found that miR-324-5p regulated the
differential expression of CUEDC2 during monocyte to macro-
phage differentiation. The decreased expression of miR-324-
5p allowed the higher expression of CUEDC2 in macrophages.
We also showed that macrophages isolated from fresh colon tu-
mor samples had highmiR-324-5p expression levels. Our finding
suggests that miR-324-5p is a potential oncomir, which confers1990 Cell Reports 7, 1982–1993, June 26, 2014 ª2014 The AuthorsTAMs the ability to produce excess tu-
mor-promoting cytokines through inhibit-
ing CUEDC2 expression.
It has been reported that IL-4 pro-
motes colon malignancies by inhibitingapoptosis (Todaro et al., 2008) and promoting survival of cancer
stem cells (Todaro et al., 2007). In accordance with these re-
ports, we found that the levels of IL-4 expression in colon can-
cer tissues were significantly higher than that in normal adjacent
tissues. It is considered that IL-4 treatment gives rise to M2
macrophages (Gordon, 2003). Emerging evidence demon-
strated that, in contrast to the binary M1/M2 definition, macro-
phages can be polarized to a mixed-phenotype state under
certain physiological and pathological conditions (Biswas
et al., 2008; Karnevi et al., 2014; Sica and Mantovani, 2012).
In particular, TAMs are M2-like cells but often share features
of both M1 and M2 macrophages (Biswas and Mantovani,
2010; Qian and Pollard, 2010). Our data show that the defi-
ciency of CUEDC2 in murine and human macrophages both re-
sulted in excessive production of proinflammatory cytokines,
and IL-4 induced significant decreased expression level of
CUEDC2 in macrophages. Moreover, elevated IL-4 in tumor
microenvironment and the decreased expression of CUEDC2
in TAMs were observed in colon cancer. Therefore, our data
suggested that IL-4 may enhance the proinflammatory state
of TAMs through modulating CUEDC2 protein level in colon
cancer.
In summary, our results demonstrated that miR-324-5p-regu-
lated CUEDC2 expression is critical for maintaining the appro-
priate function of macrophages, and the dysregulation of miR-
324-5p-CUEDC2 axis is associated with colon inflammation
and tumorigenesis. Our findings provide insights to understand
the complex pathogenic progress of colon cancer.
EXPERIMENTAL PROCEDURES
Reagents
Anti-mouse CUEDC2 (4839) was from ProSci; anti-human CUEDC2 was pre-
pared in our laboratory. Anti-human IL-4 for immunohistochemical (IHC) was
from Abcam (ab9622). The microRNA mimics and inhibitors mIRIDIAN
microRNA Mimic Negative Control (CN-002000-01-20), hsa-miR-324-5p
mimic (C-300704-03-0020), hsa-miR-326 mimic (C-300699-03-0020), hsa-
miR-330-5pmimic (C-301082-01-0020), miRIDIANmicroRNA Hairpin Inhibitor
Negative Control (IN-001005-01-20), and hsa-miR-324-5p inhibitor (IH-
300704-05-0020) were from Dharmacon. The customized human CUEDC2,
c-MYC siRNAs, and nontargeting siRNAs were synthesized from Invitrogen.
RhGM-CSF (215-GM), rhM-CSF (216-MC), rmM-CSF (416-ML), rhIL-4(204-
IL), TNF-a (210-TA), and IL-1b (201-LB) were from R&D Systems; LPS
(L2630) was from Sigma.
Cell Culture
Human peripheral blood samples were obtained from healthy donors from the
department of blood transfusion, affiliated hospital of AcademyofMilitaryMed-
ical Sciences (AMMS) following the National Institutes of Health (NIH) Guide for
the use of human samples and with the approval of the Scientific Investigation
Board of affiliated hospital of AMMS. Monocytes were purified from peripheral
blood mononuclear cells (PBMCs) with Monocyte Isolation Kit II (Miltenyi
Biotec, 130-091-153) according themanufacturer’s instruction. Primarymono-
cytes were cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal
calf serum (FCS) and 2 mM glutamine, with penicillin (100 U/ml) and strepto-
mycin (100 mg/ml). For macrophage differentiation, monocytes were cultured
for 7 days in presence of rhGM-CSF (10 ng/ml) or rhM-CSF (25 ng/ml).
Bone marrows from mice were cultured in RPMI-1640 medium for 6 hr, and
floating cells were removed to enriched monocytes. BMDMs were generated
by treating monocytes with rmM-CSF (25 ng/ml) for 7 days. For obtaining peri-
toneal macrophages, peritoneal exudate cells were cultured for 4 hr, and the
attached cells were collected. HeLa cells were cultured in DMEMmedium con-
taining 10% (v/v) FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin. Details of flow cytometry analysis for macrophage purity and
differentiation are provided in the Supplemental Experimental Procedures.
Mice
All animal experiments were performed in accordance with the NIH guide for
the care and use of laboratory animals and with the approval of the Institutional
Animal Care and Use Committee of the National Center of Biomedical Anal-
ysis. Details of Cuedc2/ mice generation are provided in the Supplemental
Experimental Procedures.
DSS-Induced Colitis
Mice (female, 6–8 weeks old) were treated with 2.5%DSS (MW36,000–50,000
Da; MP Biomedicals, MP-0216011050) in drinking water for 6 days, followed
by regular water up to 9 days. Bodyweight loss, rectal bleeding, and stool con-
sistency were monitored daily. Scoring for stool consistency and occult blood
was done as described (Zaki et al., 2010). Colons were fixed with 10% (v/v)
paraformaldehyde and stained with hematoxylin and eosin. Histological
scores (Maeda et al., 2005) were determined as follows: no ulcers = 0; moder-
ate mucosal inflammation without ulcer = 1; severe mucosal inflammation with
ulcer (<3 mm) = 2, with ulcer (3–6 mm) = 3, with ulcer (6–9 mm) = 4, with ulcer
(>9 mm) = 5. Adoptive transplantation of macrophages was performed as
described (Arranz et al., 2012; Munitz et al., 2010). Disease activity index
(DAI) was calculated as described (Kim et al., 2010). The score of weight
loss was calculated as follows: weight loss, <1% = 0; 1%–5% = 1; 6%–
15% = 2; 16%–25% = 3; >25% = 4.
Colitis-Associated Cancer
Colitis-associated cancer (CAC) was induced as described (Neufert et al.,
2007). Briefly, mice were injected intraperitoneally (i.p.) with 8.5 mg/kg AOMCat day 0. After 10 days, mice were treated with 2.0% DSS for 6 days, followed
by regular drinking water for 2 weeks. This cycle was repeated twomore times,
and mice were sacrificed 4 weeks after the last DSS cycle. Colons were
stained with 1% Alcian Blue after washing several times with PBS. The tumor
number and size weremeasuredwith ImageJ software. Thewhole colons were
fixed as ‘‘swiss rolls’’ in 10% formalin and paraffin embedded for histological
analyses. Mucosal hyperplasia scores were assigned as described (Zaki
et al., 2011).
Patient Samples
Formalin-fixed and paraffin-embedded CRC samples in this study were from
the tissue bank of the department of pathology at the affiliated hospital of
AMMS. All tumors were primary and untreated before surgery and the speci-
mens were anonymous. Tumor tissues were collected in compliance with
the regulations approved by Scientific Investigation Board of the hospital.
IHC staining and scoring for CUEDC2 and IL-4 was conducted as described
previously (Bai et al., 2013; Gao et al., 2011). The infiltrated macrophages
were stained with anti-human CD68 antibody (Zeta, Z2071) on the consecutive
slides. Microscopic images of colon cancer slides were acquired with Nano
Zoomer Digital Pathology (HAMAMATSU, HT 2.0). The slides were analyzed
by two independent pathologists.
TAM Isolation
TAMs of CRC were isolated from freshly removed tumors of untreated
patients. Solid tumors were mechanically dispersed and tumor pieces were
then dissociated in 0.3% collagenase VI (Sigma-Aldrich) overnight at 37C fol-
lowed by stirring with 0.125% (WT/v) trypsin (Sigma-Aldrich) for 45 min at
37C. Disaggregated cells were washed two times with incomplete RPMI
1640 medium, and macrophages were sorted by flow cytometry with PE-
anti-CD68 (Miltenyi Biotec).
RNA Isolation and qPCR
Total RNA was extracted with TRIzol reagent (Invitrogen, 15596-026). Total
RNAs (500–1,000 ng) were subjected to oligo(dT)-primed reverse transcription
with PrimeScript RT reagent Kit (Takara, DRR037A). To determine relative
mRNA level, qPCRs were performed using SYBR Premix Ex Taq II (Takara,
DRR081A), and gene expression was normalized to that of GAPDH. Relative
levels of microRNAs expression were measured as described (Li et al., 2010).
All qPCRassayswere run onAppliedBiosystems7300Real-TimePCRsystem.
TaqMan MicroRNA assays (Applied Biosystems) were used for microRNA
quantification: miR-324-5p, 000539; miR-326, 000542; miR-330-5p, 002230;
U6 small nuclear RNA, 001973. All qPCR primers for mRNAs detection will
be provided upon request.
ELISA
BMDMs were treated with LPS (100 ng/ml) for 12 hr, and culture supernatants
were harvested. The concentrations of cytokines were measured by ELISA
(R&D Systems, D6050, DTA00C, and DP400).
Luciferase Assay
HeLa cells were transfected using Lipofectamine 2000 (Invitrogen, 11668-019)
with 50 ng CMV-driven pMIR Firefly luciferase CUEDC2 30 UTR reporter
plasmid, 5 ng HSV-TK-driven Renilla luciferase plasmid, and 100 pmol miR-
324-5p mimic or control mimic. Forty-eight hours after transfection, cells
were harvested, and luciferase activities were measured as previously
described (Li et al., 2010).
Electroporation
Amaxa Nucleofector Kits (Lonza) were used for transfection of monocytes and
macrophages, according to the manufacturer’s guidelines (VPA-1007 and
VPA-1008, respectively). microRNA (100 pmol) mimics or inhibitors were
used to transfect 2 3 106 cells. After electroporation, cells were collected 24
or 48 hr after transfection.
Immunoblot Analysis
Cells were lysed with lysis buffer (20mMTris [pH 7.5], 0.5% (v/v) Nonidet P-40,
10 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol) containingell Reports 7, 1982–1993, June 26, 2014 ª2014 The Authors 1991
complete protease inhibitor cocktail (Roche, 04693132001). Cell lysates were
separated by SDS-PAGE and analyzed by immunoblot. Proteins were visual-
ized by enhanced chemiluminescence according to the manufacturer’s in-
structions (Vigorous Biotechnology).
Statistical Analysis
Statistical analysis data are expressed as mean ± SEM. Significance was
assessed by two-tailed Student’s t test, one-way ANOVA test or Mann-
Whitney U test. p values less than 0.05 were considered as statistical signifi-
cant. Statistical calculations were performed using SPSS 13.0.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.05.007.
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